Expert Chaslau Koniukh
  • Companies
  • Global investment
  • Investors
  • Terminology
  • Economy
  • Stock Market
  • World exchanges
  • Tech and Marketing
atai life sciences
Stock Market

Startup ATAI Life Sciences plans an IPO

23.01.2022
2 min read

ATAI Life Sciences wants to go public on NASDAQ

Biopharmaceutical company ATAI Life Sciences is going public. It is planned to raise $100 million during the IPO. Now, private investors have invested more than $362 million in the startup. ATAI specializes in developing drugs based on psychedelic substances.
After the last funding round, the startup was valued at $2 billion, making it considered a “unicorn.”
According to the company’s plans, the NASDAQ stock exchange was chosen for the initial public offering, but the exact date of the IPO is not yet known. Major banks such as Credit Suisse and Citigroup are providing exit services.
The field of activity of ATAI is the production of drugs that help in treating depression, anxiety, phobias and other psychological problems.
As part of these drugs are psychoactive substances that affect the emotional state and perception of reality, changing it. The company employs 50 people who work in different cities. The main office is in Berlin, there are also offices in San Diego and New York. The drugs are being tested, but so far none of them has received approval from the regulatory authorities. Altogether, ATAI offers more than 10 drugs for various problems.
One of ATAI’s investors is Peter Thiel, who co-founded the PayPal payment system and has invested 10 million euros in the project through his own venture capital firm. According to Thiel, he became interested in ATAI because of their idea to help with mental disorders. The startup demonstrates the importance and seriousness of the problem by putting mental illnesses on a par with other diseases.ATAIATAI Life Sciences was founded in Germany in 2018; the company was one of the first on the market to start using psychedelics to treat psychiatric problems. To do this, the startup used a synthetic substitute for psilocybin, which is the main active ingredient of hallucinogenic mushrooms.
According to studies, more than 100 million people in the world suffer from various kinds of depressive disorders, for which traditional therapy is ineffective. ATAI aims to help these patients, and to do this, the experts are working on a study of the effects of psychedelics on mental states.
In the structure of ATAI there are 11 projects, which are engaged in research and search of new methods of treatment of various mental illnesses. The results of the company’s activities are already visible, the drugs are being tested and show good progress in patients. Investors consider the startup promising, and investments are growing, despite psilocybin’s dubious reputation. Its effects have not been fully investigated, which prevents widespread use for medical purposes.

Tags: Stock Market
0
Previous Post Japan invests in the development of hydrogen energy Next Post BlackRock analysts: global ETFs are actively developing

You Might Also Like

The European Union created a fund
Stock Market
The European Union created a fund of 5 billion euros to help businesses
13.05.2022
Paytm
Stock Market
Alibaba sold part of its shares in the Indian fintech Paytm
25.04.2023
RUSNANO company
Stock Market
RUSNANO’s subsidiary Atea Pharmaceuticals is listed on the New York Stock Exchange
07.07.2021
Ola Electric
Stock Market
E-scooter maker Ola Electric reaches US$7 bn valuation
19.11.2024
LG dollar-denominated bonds
Stock Market
LG Electronics issues dollar-denominated bonds for the first time in 12 years
15.08.2024
Uber shares
Stock Market
Uber shares rise on positive 2022 performance
19.05.2023

Popular Posts

  • Li Ka Shing: How can success be achieved without money and education?
  • Skolkovo analysts: the Russian energy market is suffering losses
  • Ingeborg Mootz: a woman who became a stock player at the age of 75
  • Analysts: Egypt’s economy to continue falling in 2023

Editor's Picks

Chaslau Koniukh
Analytics

American bankers from JPMorgan and Goldman Sachs advise to invest in gold: review by Chaslau Koniukh.

Press Secretary
17.08.2020
Expert Chaslau Koniukh
Analytics

Chaslau Koniukh on the analysts’ opinion on the key stake size change soon

Press Secretary
18.06.2020
expert Chaslau Koniukh
Analytics

Chaslau Koniukh: Internet trade market in Russia may reach 2.78 trillion rubles.

Press Secretary
30.05.2020
Will the U.S. oil shale industry be able to quickly recover from the crisis: A Review by Chaslau Koniukh
Analytics

Will the U.S. oil shale industry be able to quickly recover from the crisis: A Review by Chaslau Koniukh

Press Secretary
16.05.2020

Popular Posts

  • Li Ka Shing: How can success be achieved without money and education?
  • Skolkovo analysts: the Russian energy market is suffering losses
  • Ingeborg Mootz: a woman who became a stock player at the age of 75
  • Analysts: Egypt’s economy to continue falling in 2023
  • Businessman Chuck Feeney: the man who gave the world Duty Free
Expert Chaslau Koniukh
  • Facebook
  • Twitter
  • Instagram

© 2024 CHASLAU KONIUKH. ALL RIGHTS RESERVED. Expert in marketing and project management, international investments, financial analyst.

Menu

  • Biography
  • Companies and corporations
  • Global investment
  • Investors and Entrepreneurs
  • Economy
  • Market terminology
  • Stock Market
  • World exchanges
  • Tech and Marketing
  • Analytics